Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063401 · ClinicalTrials.gov registry record · Phase 2
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00063401 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 39 participants.
The verdict
NCT00063401, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Cetuximab:
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063401
The ClinicalTrials.gov registry entry for NCT00063401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00063401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063401 about?
NCT00063401 is a clinical study titled "Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer". The purpose of this study is to determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.
What is the current status of trial NCT00063401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2003-09. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00063401?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Cetuximab: (BIOLOGICAL).
Who is sponsoring clinical trial NCT00063401?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.